Halligan, S.
Tolan, D.
Amitai, M. M.
Hoeffel, C.
Kim, S. H.
Maccioni, F.
Morrin, M. M.
Mortele, K. J.
Rafaelsen, S. R.
Rimola, J.
Schmidt, S.
Stoker, J.
Yang, J.
Funding for this research was provided by:
UCLH Biomedical Research Centre (BRC)
Article History
Received: 19 January 2020
Accepted: 19 March 2020
First Online: 19 April 2020
Compliance with ethical standards
:
: The scientific guarantor of this publication is SH.
: DT declares lecture honoraria from Guerbet; JR declares research funding from Abbvie and Genentech, and lecture honoraria from Abbvie, Gilead and Janssen. JR is an advisory board member for Takeda, TiGenix, Gilead and Robarts Clinical Trials. JS declares institutional research consultancy for Robarts Clinical Trials.SH, MMA, CH, SHK, FM, MMM, KJM, SRR, SS and JY declare no relationships with any companies whose products or services may be related to the subject matter of the article.
: No complex statistical methods were necessary for this paper.
: Not applicable.
: Institutional Review Board approval was not required because the research was guideline development.
: • Prospective• Multicentre• Guideline development